Know Cancer

forgot password

A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Phase 3
18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Participants were treated for 21-day cycles until disease progression, unacceptable
toxicity, or consent withdrawal. After treatment discontinuation, participants were followed
until end of study or death or receipt of new anticancer therapy, whichever was first.

Inclusion Criteria:

- Histologically documented breast cancer (either primary or metastatic site) that is
ER-negative, PR-negative, and HER2 non-overexpressing by immunohistochemistry (0, 1) or
fluorescence in situ hybridization (FISH).

Triple-negative tumors were defined by the following criteria:

- HER2-non-overexpressing: FISH-negative (defined by ratio <2.2) or,
immunohistochemical (IHC) 0, IHC 1+ or, IHC 2+ or IHC 3+ and FISH-negative.

- ER- and PR-negative: <10% tumor staining by immunohistochemistry (IHC).

- Never having received chemotherapy for metastatic disease or, having received 1
or 2 prior chemotherapy regimens in the metastatic setting (Prior
adjuvant/neoadjuvant therapy was allowed);

- Metastatic breast cancer (Stage IV) with measurable disease by RECIST 1.1

- Female, ≥18 years of age;

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

- Organ and marrow function as follows: absolute neutrophil count (ANC) ≥1500/mm3,
platelets ≥100,000/dL, hemoglobin ≥9 g/dL, bilirubin ≤1.5 mg/dL, serum
creatinine ≤1.5 mg/dL or creatinine clearance ≥60 mL/min, alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the upper
limit of normal if no liver involvement or ≤5 times the upper limit of normal
with liver involvement;

- Radiation therapy completed at least 14 days before study dosing on day 1;
radiated lesions may not have served as measurable disease;

- Central nervous system metastases allowed if subject did not require steroids,
whole brain radiation therapy (XRT), gamma/cyber knife, and brain metastases
were clinically stable without symptomatic progression;

- For women of child bearing potential, documented negative pregnancy test within
two weeks of study entry and agreement to acceptable birth control during the
duration of the study therapy;

- Tissue block (primary or metastatic) or readily available fresh frozen tumor
tissue for PARP expression and other pharmacogenomic studies recommended
(although its absence will not exclude subjects from participating);

- No other diagnosis of malignancy (with exception of non melanoma skin cancer or
a malignancy diagnosed ≥5 years ago);

- Obtained informed consent;

- Capability to understand and comply with the protocol and signed informed
consent document.

Exclusion Criteria:

- Systemic anticancer therapy within 14 days of the first dose of study drug;

- Prior treatment with gemcitabine, carboplatin, cisplatin or iniparib

- Had not recovered to grade ≤1 from adverse events (AEs) per National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE) v3.0 or to within 10% of
baseline values due to investigational drugs or other medications administered more
than 30 days prior to study enrollment;

- Major medical conditions that might have affected study participation (e.g.
uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection,
cardiac disease);

- Concurrent radiation therapy intended to treat primary tumor not permitted throughout
the course of the study; palliative radiation was acceptable;

- Leptomeningeal disease or brain metastases requiring steroids or other therapeutic

- Pregnancy or breastfeeding;

- Inability or unwillingness to abide by the study protocol or cooperate fully with the
investigator or designee.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

progression free survival

Outcome Description:

Progression free survival was defined as the time interval from the date of randomization to the date of first disease progression (as assessed by Independent Radiologic Review (IRR) based on Response Evaluation Criteria in Solid Tumor (RECIST) criteria), or the date of death due to any cause, whichever occurred first. In the absence disease progression or death, the participant was censored at the date of the last valid tumor assessment performed before the cut-off date.

Outcome Time Frame:

until cut-off date established from deaths rate

Safety Issue:


Principal Investigator

Clinical Sciences & Operations

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

July 2009

Completion Date:

February 2012

Related Keywords:

  • Breast Cancer
  • triple negative breast cancer
  • metastatic breast cancer
  • Triple negative metastatic breast cancer
  • Breast Neoplasms



Research Site Alabaster, Alabama  
Research Site Mesa, Arizona  
Research Site Bentonville, Arkansas  
Research Site Anaheim, California  
Research Site Boulder, Colorado  
Research Site Washington, District of Columbia  
Research Site Boca Raton, Florida  
Research Site Albany, Georgia  
Research Site Boise, Idaho  
Research Site Arlington Heights, Illinois  
Research Site Bloomington, Indiana  
Research Site Hays, Kansas  
Research Site Baltimore, Maryland  
Research Site Beverly, Massachusetts  
Research Site Battle Kreek, Michigan  
Research Site Alexandria, Minnesota  
Research Site Hattiesburg, Mississippi  
Research Site Branson, Missouri  
Research Site Grand Island, Nebraska  
Research Site Las Vegas, Nevada  
Research Site Hooksett, New Hampshire  
Research Site Belleville, New Jersey  
Research Site Albuquerque, New Mexico  
Research Site Albany, New York  
Research Site Asheville, North Carolina  
Research Site Akron, Ohio  
Research Site Bend, Oregon  
Research Site Allentown, Pennsylvania  
Research Site Chattanooga, Tennessee  
Research Site Abilene, Texas  
Research Site Ivins, Utah  
Research Site Abington, Virginia  
Research Site Auburn, Washington  
Reserach Site Billings, Montana  
Reserach Site Durham, North Carolina  
Reserach Site Columbia, South Carolina  
Research Sites Seattle, Washington